The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.

Innovent Unveils Phase 3 Study Outcomes of Mazdutide for Weight Control at the ADA's 84th Scientific Sessions.

The European Commission has approved Roche's OCREVUS for subcutaneous use, making it the first and only twice-yearly injection for relapsing and primary progressive multiple sclerosis.

Alnylam Announces Successful Topline Results from HELIOS-B Phase 3 Trial of Vutrisiran, Showing Statistical Significance in Primary and All Secondary Endpoints in Both Combined and Monotherapy Groups.

This IND will enable the assessment of ADI-270, for the therapeutic intervention in relapsed/refractory renal cell carcinoma.

Scholar Rock Unveils New SRK-439 Preclinical Data Showing Notable Lean Mass Preservation and Reduced Fat Mass Rebound After Stopping GLP-1 Receptor Agonist.

Altimmune Shares Findings on Pemvidutide's Impact on Cardioinflammatory Lipid Levels at ADA’s 84th Annual Scientific Sessions.

Novo Nordisk A/S: Mim8 showed better reductions in annual bleeding rates (ABR) than on-demand treatments and previous prophylaxis in haemophilia A patients.

In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.

Sun Pharma's GL0034 (Utreglutide) Showcases Remarkable Weight Loss and Metabolic Improvements in Obesity at ADA's 84th Session.

Takeda Reveals New Data from Phase 2b Study of Mezagitamab, Showing Potential to Innovate Primary Immune Thrombocytopenia Treatment.

Bristol Myers Squibb's application for subcutaneous nivolumab has been validated by the European Medicines Agency.